Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902866 | 1.00 | EGFR (0.58) | EGFRNR4A1NR4A2NR4A3MAOB | |
| SCHEMBL7841747 | 0.88 | EGFR (0.47) | EGFRNR4A1NR4A2NR4A3MAOB | |
| SCHEMBL14785037 | 0.82 | MAOB (0.59) | MAOBRAB9ASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL28595923 | 0.81 | EPHX2 (0.57) | RAB9ASMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL2438485 | 0.81 | EPHX2 (0.57) | RAB9ASMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL1278317 | 0.81 | EPHX2 (0.57) | RAB9ASMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL7094216 | 0.81 | EPHX2 (0.57) | RAB9ASMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL10133110 | 0.80 | RAB9A (0.76) | RAB9ASMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL2439457 | 0.79 | MAPT (0.56) | RAB9ASMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL16178630 | 0.79 | NPC1 (0.54) | SRD5A2RAB9AMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20070032497-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7112600-B1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2006-09-26 | — | — | US | disclosed |
| US-6770666-B2 | A THERAPEUTIC AGENT FOR TREATING HEPATITIS C, BASED ON POLYMERASE INHIBITORY ACTIVITY | JAPAN TOBACCO INC. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | HAVCR2, ZC3HAV1, POLR1C | EGFR 4716/4885NR4A1 2606/4885NR4A2 3583/4885 |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | EGFR 4630/4885NR4A1 1083/4885NR4A2 1851/4885 |
| US-20070032497-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | EGFR 4648/4885NR4A1 1261/4885NR4A2 1760/4885 |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, SLC10A1 | EGFR 4032/4885NR4A1 1483/4885NR4A2 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.